UK okays Alexion drug costing up to $2 million but wants price cut

LONDON (Reuters) - A new drug to treat a rare inherited bone disorder that was developed by Alexion Pharmaceuticals and could cost up to 1.5 million pounds ($2 million) a year per patient has been cleared for use by Britain's health cost watchdog.